Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01658878 · OUTCOME

Number of Participants With Anti-drug Antibodies (ADA)

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer · Source last updated 2025-12-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)

What was measured

Baseline ADA Positive: Participant with baseline ADA-positive sample ADA Positive: Participant with at least one ADA-positive sample relative to baseline Persistent Positive (PP): ADA-positive sample at 2 or more consecutive timepoints Not PP-Last Sample Positive: Not persistent but with ADA-positive sample at the last sampling timepoint Other Positive: Not persistent but some ADA-positive samples with the last sample being negative ADA Negative: Participant with no ADA-positive sample after initiation of treatment

Analysis population: All treated participants in Cohort 1 and 2 with baseline and at least 1 post-baseline assessment. Pre-specified to be reported for Cohort 1 and 2 only.

Groups in this outcome

Cohort 1 Uninfected HCC: Treatment 1

Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.1 mg/kg every 2 weeks

Cohort 1 Uninfected HCC: Treatment 2

Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.3 mg/kg every 2 weeks

Cohort 1 Uninfected HCC: Treatment 3

Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 1 mg/kg every 2 weeks

Cohort 1 Uninfected HCC: Treatment 4

Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 3 mg/kg every 2 weeks

Cohort 1 Uninfected HCC: Treatment 5

Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 10 mg/kg every 2 weeks

Cohort 1 HCV Infected: Treatment 6

Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 0.3 mg/kg every 2 weeks

Cohort 1 HCV Infected: Treatment 7

Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 1 mg/kg every 2 weeks

Cohort 1 HCV Infected: Treatment 8

Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 3 mg/kg every 2 weeks

Cohort 1 HBV Infected: Treatment 9

Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.1 mg/kg every 2 weeks

Cohort 1 HBV Infected: Treatment 10

Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.3 mg/kg every 2 weeks

Cohort 1 HBV Infected: Treatment 11

Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 1 mg/kg every 2 weeks

Cohort 1 HBV Infected: Treatment 12

Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 3 mg/kg every 2 weeks

Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1

Dose Expansion: Uninfected hepatocellular carcinoma (HCC) participants who are sorafenib naive/intolerant received nivolumab 3 mg/kg every 2 weeks

Cohort 2 Uninfected Sorafenib Progressors: Treatment 2

Dose Expansion: Uninfected hepatocellular carcinoma (HCC) participants who are sorafenib progressors received nivolumab 3 mg/kg every 2 weeks

Cohort 2 HCV Infected: Treatment 3

Dose Expansion: Hepatitis C (HCV)-infected participants received nivolumab 3 mg/kg every 2 weeks

Cohort 2 HBV Infected: Treatment 4

Dose Expansion: Hepatitis B (HBV)-infected participants received nivolumab 3 mg/kg every 2 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 1 Uninfected HCC: Treatment 11
Cohort 1 Uninfected HCC: Treatment 23
Cohort 1 Uninfected HCC: Treatment 33
Cohort 1 Uninfected HCC: Treatment 43
Cohort 1 Uninfected HCC: Treatment 512
Cohort 1 HCV Infected: Treatment 63
Cohort 1 HCV Infected: Treatment 74
Cohort 1 HCV Infected: Treatment 83
Cohort 1 HBV Infected: Treatment 95
Cohort 1 HBV Infected: Treatment 103
Cohort 1 HBV Infected: Treatment 113
Cohort 1 HBV Infected: Treatment 124
Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 153
Cohort 2 Uninfected Sorafenib Progressors: Treatment 254
Cohort 2 HCV Infected: Treatment 344
Cohort 2 HBV Infected: Treatment 450

Reported measurements

Baseline ADA Positive
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort 1 Uninfected HCC: Treatment 10Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 20Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 30Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 41Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 50Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 60Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 70Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 80Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 90Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 100Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 110Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 120Not reportedNot reportedNot reportedNot reported
Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 110Not reportedNot reportedNot reportedNot reported
Cohort 2 Uninfected Sorafenib Progressors: Treatment 23Not reportedNot reportedNot reportedNot reported
Cohort 2 HCV Infected: Treatment 35Not reportedNot reportedNot reportedNot reported
Cohort 2 HBV Infected: Treatment 41Not reportedNot reportedNot reportedNot reported
ADA Positive
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort 1 Uninfected HCC: Treatment 10Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 22Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 32Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 40Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 51Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 62Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 71Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 80Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 91Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 101Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 111Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 121Not reportedNot reportedNot reportedNot reported
Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 118Not reportedNot reportedNot reportedNot reported
Cohort 2 Uninfected Sorafenib Progressors: Treatment 219Not reportedNot reportedNot reportedNot reported
Cohort 2 HCV Infected: Treatment 316Not reportedNot reportedNot reportedNot reported
Cohort 2 HBV Infected: Treatment 47Not reportedNot reportedNot reportedNot reported
ADA Positive [Persistent Positive (PP)]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort 1 Uninfected HCC: Treatment 10Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 20Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 31Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 40Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 50Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 60Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 70Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 80Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 91Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 100Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 110Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 120Not reportedNot reportedNot reportedNot reported
Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 12Not reportedNot reportedNot reportedNot reported
Cohort 2 Uninfected Sorafenib Progressors: Treatment 21Not reportedNot reportedNot reportedNot reported
Cohort 2 HCV Infected: Treatment 33Not reportedNot reportedNot reportedNot reported
Cohort 2 HBV Infected: Treatment 40Not reportedNot reportedNot reportedNot reported
ADA Positive [Not PP-Last Sample Positive]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort 1 Uninfected HCC: Treatment 10Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 22Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 31Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 40Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 51Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 60Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 71Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 80Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 90Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 100Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 111Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 120Not reportedNot reportedNot reportedNot reported
Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 14Not reportedNot reportedNot reportedNot reported
Cohort 2 Uninfected Sorafenib Progressors: Treatment 23Not reportedNot reportedNot reportedNot reported
Cohort 2 HCV Infected: Treatment 39Not reportedNot reportedNot reportedNot reported
Cohort 2 HBV Infected: Treatment 41Not reportedNot reportedNot reportedNot reported
ADA Positive [Other Positive]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort 1 Uninfected HCC: Treatment 10Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 20Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 30Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 40Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 50Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 62Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 70Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 80Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 90Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 101Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 110Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 121Not reportedNot reportedNot reportedNot reported
Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 112Not reportedNot reportedNot reportedNot reported
Cohort 2 Uninfected Sorafenib Progressors: Treatment 215Not reportedNot reportedNot reportedNot reported
Cohort 2 HCV Infected: Treatment 34Not reportedNot reportedNot reportedNot reported
Cohort 2 HBV Infected: Treatment 46Not reportedNot reportedNot reportedNot reported
Neutralizing Positive
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort 1 Uninfected HCC: Treatment 10Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 20Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 30Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 40Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 50Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 60Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 70Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 80Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 91Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 100Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 110Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 120Not reportedNot reportedNot reportedNot reported
Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 10Not reportedNot reportedNot reportedNot reported
Cohort 2 Uninfected Sorafenib Progressors: Treatment 22Not reportedNot reportedNot reportedNot reported
Cohort 2 HCV Infected: Treatment 30Not reportedNot reportedNot reportedNot reported
Cohort 2 HBV Infected: Treatment 40Not reportedNot reportedNot reportedNot reported
ADA Negative
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort 1 Uninfected HCC: Treatment 11Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 21Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 31Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 43Not reportedNot reportedNot reportedNot reported
Cohort 1 Uninfected HCC: Treatment 511Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 61Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 73Not reportedNot reportedNot reportedNot reported
Cohort 1 HCV Infected: Treatment 83Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 94Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 102Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 112Not reportedNot reportedNot reportedNot reported
Cohort 1 HBV Infected: Treatment 123Not reportedNot reportedNot reportedNot reported
Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 135Not reportedNot reportedNot reportedNot reported
Cohort 2 Uninfected Sorafenib Progressors: Treatment 235Not reportedNot reportedNot reportedNot reported
Cohort 2 HCV Infected: Treatment 328Not reportedNot reportedNot reportedNot reported
Cohort 2 HBV Infected: Treatment 443Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        1
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        0
      7. group Id
        OG006
        value
        0
      8. group Id
        OG007
        value
        0
      9. group Id
        OG008
        value
        0
      10. group Id
        OG009
        value
        0
      11. group Id
        OG010
        value
        0
      12. group Id
        OG011
        value
        0
    title
    Baseline ADA Positive
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        2
      3. group Id
        OG002
        value
        2
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        1
      6. group Id
        OG005
        value
        2
      7. group Id
        OG006
        value
        1
      8. group Id
        OG007
        value
        0
      9. group Id
        OG008
        value
        1
      10. group Id
        OG009
        value
        1
      11. group Id
        OG010
        value
        1
      12. group Id
        OG011
        value
        1
    title
    ADA Positive
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        1
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        0
      7. group Id
        OG006
        value
        0
      8. group Id
        OG007
        value
        0
      9. group Id
        OG008
        value
        1
      10. group Id
        OG009
        value
        0
      11. group Id
        OG010
        value
        0
      12. group Id
        OG011
        value
        0
    title
    ADA Positive [Persistent Positive (PP)]
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        2
      3. group Id
        OG002
        value
        1
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        1
      6. group Id
        OG005
        value
        0
      7. group Id
        OG006
        value
        1
      8. group Id
        OG007
        value
        0
      9. group Id
        OG008
        value
        0
      10. group Id
        OG009
        value
        0
      11. group Id
        OG010
        value
        1
      12. group Id
        OG011
        value
        0
    title
    ADA Positive [Not PP-Last Sample Positive]
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        2
      7. group Id
        OG006
        value
        0
      8. group Id
        OG007
        value
        0
      9. group Id
        OG008
        value
        0
      10. group Id
        OG009
        value
        1
      11. group Id
        OG010
        value
        0
      12. group Id
        OG011
        value
        1
    title
    ADA Positive [Other Positive]
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        0
      7. group Id
        OG006
        value
        0
      8. group Id
        OG007
        value
        0
      9. group Id
        OG008
        value
        1
      10. group Id
        OG009
        value
        0
      11. group Id
        OG010
        value
        0
      12. group Id
        OG011
        value
        0
    title
    Neutralizing Positive
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        1
      4. group Id
        OG003
        value
        3
      5. group Id
        OG004
        value
        11
      6. group Id
        OG005
        value
        1
      7. group Id
        OG006
        value
        3
      8. group Id
        OG007
        value
        3
      9. group Id
        OG008
        value
        4
      10. group Id
        OG009
        value
        2
      11. group Id
        OG010
        value
        2
      12. group Id
        OG011
        value
        3
    title
    ADA Negative
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    2. group Id
      OG001
      value
      3
    3. group Id
      OG002
      value
      3
    4. group Id
      OG003
      value
      3
    5. group Id
      OG004
      value
      12
    6. group Id
      OG005
      value
      3
    7. group Id
      OG006
      value
      4
    8. group Id
      OG007
      value
      3
    9. group Id
      OG008
      value
      5
    10. group Id
      OG009
      value
      3
    11. group Id
      OG010
      value
      3
    12. group Id
      OG011
      value
      4
    units
    Participants
description
Baseline ADA Positive: Participant with baseline ADA-positive sample ADA Positive: Participant with at least one ADA-positive sample relative to baseline Persistent Positive (PP): ADA-positive sample at 2 or more consecutive timepoints Not PP-Last Sample Positive: Not persistent but with ADA-positive sample at the last sampling timepoint Other Positive: Not persistent but some ADA-positive samples with the last sample being negative ADA Negative: Participant with no ADA-positive sample after initiation of treatment
groups
  1. description
    Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.1 mg/kg every 2 weeks
    id
    OG000
    title
    Cohort 1 Uninfected HCC: Treatment 1
  2. description
    Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.3 mg/kg every 2 weeks
    id
    OG001
    title
    Cohort 1 Uninfected HCC: Treatment 2
  3. description
    Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 1 mg/kg every 2 weeks
    id
    OG002
    title
    Cohort 1 Uninfected HCC: Treatment 3
  4. description
    Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 3 mg/kg every 2 weeks
    id
    OG003
    title
    Cohort 1 Uninfected HCC: Treatment 4
  5. description
    Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 10 mg/kg every 2 weeks
    id
    OG004
    title
    Cohort 1 Uninfected HCC: Treatment 5
  6. description
    Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 0.3 mg/kg every 2 weeks
    id
    OG005
    title
    Cohort 1 HCV Infected: Treatment 6
  7. description
    Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 1 mg/kg every 2 weeks
    id
    OG006
    title
    Cohort 1 HCV Infected: Treatment 7
  8. description
    Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 3 mg/kg every 2 weeks
    id
    OG007
    title
    Cohort 1 HCV Infected: Treatment 8
  9. description
    Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.1 mg/kg every 2 weeks
    id
    OG008
    title
    Cohort 1 HBV Infected: Treatment 9
  10. description
    Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.3 mg/kg every 2 weeks
    id
    OG009
    title
    Cohort 1 HBV Infected: Treatment 10
  11. description
    Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 1 mg/kg every 2 weeks
    id
    OG010
    title
    Cohort 1 HBV Infected: Treatment 11
  12. description
    Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 3 mg/kg every 2 weeks
    id
    OG011
    title
    Cohort 1 HBV Infected: Treatment 12
param Type
COUNT_OF_PARTICIPANTS
population Description
All treated participants in Cohort 1 and 2 with baseline and at least 1 post-baseline assessment. Pre-specified to be reported for Cohort 1 and 2 only.
reporting Status
POSTED
time Frame
From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)
title
Number of Participants With Anti-drug Antibodies (ADA)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice